DSDudley K. Strickland

Dudley K. Strickland

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dudley K. Strickland has a total of 161 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The ligand preference of LRP1 is regulated by O-glycans

    by John Hintze, Asli B. Topaktas, Thomas D. Madsen, Shifa Jebari-Benslaiman, Bethany H. Claridge, Silvia D’ANdrea, Noortje de Haan, Lasse H. Hansen, Rob Baars, Noé Quittot, et al.

    The family of low-density lipoprotein receptor (LDLR) and LDLR-related proteins (LRPs) are endocytic receptors serving as essential regulators of multiple physiological processes including cholesterol clearance, protein reabsorption, and neuronal protein trafficking. Site-specific O-glycans modify linkers of the ligand-binding domains of LRPs. Most linker O-glycans are initiated exclusively by GALNT11, 1 of 20 polypeptide GalNAc-transferase isoenzymes. Here, we investigate the role of GALNT11 linker O-glycans in the large and widely expressed multiligand receptor LRP1. In cell models expressing LRP1 with and without GALNT11, we demonstrate that while the uptake of certain ligands such as RAP and ApoE was unaffected, uptake of neurotoxic tau and amyloid-β was altered and in opposite directions. Characterization of LRP1 linker O-glycans indicated incomplete sialic acid capping, a feature that, in MD simulations, enabled inter- and intramolecular interactions. Our findings highlight a potential regulatory mechanism of endocytic receptors and identify the ligand repertoire of LRP1 as influenced by O-glycans, with implications for neurodegenerative disease.


  • Open Access

    PAI-1 interaction with sortilin-related receptor 1 is required for lung fibrosis

    by Thomas H. Sisson, John J. Osterholzer, Lisa Leung, Venkatesha Basrur, Alexey I. Nesvizhskii, Natalya Subbotina, Mark Warnock, Daniel Torrente, Ammara Q. Virk, Sergey S. Gutor, et al.

    Mutation studies of plasminogen activator inhibitor 1 (PAI-1) have previously implied that PAI-1 promotes lung fibrosis via a vitronectin-dependent (VTN-dependent) mechanism. In the present study, employing 2 distinct murine fibrosis models and VTN-deficient mice, we found that VTN is not required for PAI-1 to drive lung scarring. This result suggested the existence of a profibrotic interaction involving the VTN-binding site on PAI-1 with an unidentified ligand. Using an unbiased proteomic approach, we identified sortilin-related receptor 1 (SorLA) as the most highly enriched PAI-1 binding partner in the fibrosing lung. Investigating the role of SorLA in pulmonary fibrosis demonstrated that deficiency of this protein protected against lung scarring in a murine model. We further found that SorLA is required for PAI-1 to promote scarring in mice, that both SorLA and PAI-1 protein levels are increased in human idiopathic pulmonary fibrosis (IPF) explants, and that these proteins are associated in IPF tissue. Finally, confocal microscopy showed that expression of SorLA in CHO cells increased cellular uptake of PAI-1, and these proteins colocalized in the cytoplasm. Together, these data elucidate a mechanism by which the potent profibrotic mediator PAI-1 drives lung fibrosis and implicate SorLA as a potential therapeutic target in IPF treatment.


  • Tale of 2 Receptors

    by Dudley K. Strickland, Joanna M. Cooper

  • Identification of Amino Acid Residues Critical for the Interaction of Fibrin with N-Cadherin

    by Sergiy Yakovlev, David A. Nyenhuis, Nico Tjandra, Dudley K. Strickland, Leonid Medved

    We recently identified N-cadherin as a novel receptor for fibrin and localized complementary binding sites within the fibrin βN-domains and the third and fifth extracellular domains (EC3 and EC5) of N-cadherin. We also hypothesized that the His16 and Arg17 residues of the βN-domains and the (Asp/Glu)-X-(Asp/Glu) motifs present in the EC3 and EC5 domains may play roles in the interaction between fibrin and N-cadherin. The primary objectives of this study were to test these hypotheses and to further clarify the structural basis for this interaction. To test our hypotheses, we first mutated His16 and Arg17 in the recombinant (β15-66)2 fragment, which mimics the dimeric arrangement of the βN-domains in fibrin, using site-directed mutagenesis. The results revealed that the mutations of both His16 and Arg17 are critical for the interaction. Next, we mutated Asp/Glu residues in the three (Asp/Glu)-X-(Asp/Glu) motifs, M1 (Asp-Phe-Glu), M2 (Glu-Ala-Glu), and M3 (Asp-Tyr-Asp), of the fibrin-binding N-cad(3-5) fragment of N-cadherin. The results showed that Asp292 and Glu294 of M1, and Asp468 and Asp470 of M3, are critical for the interaction. Our molecular modeling of the 3D structure of the EC3-EC4-EC5 domains revealed that these residues are located at the interfaces of EC3-EC4 and EC4-EC5 and that some may also be involved in calcium binding. In conclusion, our study identified amino acid residues in the fibrin βN-domains and the EC3 and EC5 domains of N-cadherin that are critical for the interaction of fibrin with N-cadherin and localized the fibrin-binding residues in the 3D structure of N-cadherin.


  • Open Access

    PAI-1 Interaction with Sortilin Related Receptor-1 is Required for Lung Fibrosis

    by Thomas H. Sisson, John J. Osterholzer, Lisa Leung, Venkatesha Basrur, Alexey Nesvizhskii, Natalya Subbotina, Mark Warnock, Daniel Torrente, Ammara Q Virk, Jeffrey C. Horowitz, et al.

    Plasminogen activator inhibitor-1 (PAI-1) has been previously shown to promote lung fibrosis via a mechanism that requires an intact vitronectin (VTN) binding site. In the present study, employing two distinct murine fibrosis models, we find that VTN is not required for PAI-1 to drive lung scarring. This result suggested the existence of a previously unrecognized profibrotic PAI-1-protein interaction involving the VTN-binding site for PAI-1. Using an unbiased proteomic approach, we identified sortilin related receptor 1 (SorlA) as the most highly enriched PAI-1 interactor in the fibrosing lung. We next investigated the role of SorlA in pulmonary fibrosis and found that SorlA deficiency protected against lung scarring in a murine model. We further show that, while VTN deficiency does not influence fibrogenesis in the presence or absence of PAI-1, SorlA is required for PAI-1 to promote scarring. These results, together with data showing increased SorlA levels in human IPF lung tissue, support a novel mechanism through which the potent profibrotic mediator PAI-1 drives lung fibrosis and implicate SorlA as a new therapeutic target in IPF treatment.

  • Open Access

    SORL1 is a receptor for tau that promotes tau seeding

    by Joanna M. Cooper, Aurelien Lathuiliere, Enming J. Su, Yuyu Song, Daniel Torrente, Youhwa Jo, Nicholas Weinrich, Jennifer Diaz Sales, Mary Migliorini, Thomas H. Sisson, et al.


  • Identification of Neural (N)-Cadherin as a Novel Endothelial Cell Receptor for Fibrin and Localization of the Complementary Binding Sites

    by Sergiy Yakovlev, Nico Tjandra, Dudley D. Strickland, Leonid Medved

    Based on the high structural homology between vascular endothelial (VE)-cadherin and neural (N)-cadherin, we hypothesized that fibrin, which is known to interact with VE-cadherin and promote angiogenesis through this interaction, may also interact with N-cadherin. To test this hypothesis, we prepared fibrin and its plasmin-produced and recombinant fragments covering practically all parts of the fibrin molecule. We also prepared the soluble extracellular portion of N-cadherin (sN-cadherin), which includes all five extracellular N-cadherin domains, and studied its interaction with fibrinogen, fibrin, and the aforementioned fibrin fragments using two independent methods, ELISA and SPR. The experiments confirmed our hypothesis, revealing that fibrin interacts with sN-cadherin with high affinity. Furthermore, the experiments localized the N-cadherin binding site within the fibrin βN-domains. Notably, the recombinant dimeric (β15-66)2 fragment, corresponding to these domains and mimicking their dimeric arrangement in fibrin, preserved the N-cadherin-binding properties of fibrin. To localize the fibrin binding site within N-cadherin, we performed ELISA and SPR experiments with (β15-66)2 and recombinant N-cadherin fragments representing its individual extracellular domains and combinations thereof. The results obtained indicate that the interaction of fibrin with N-cadherin occurs through the third and fifth extracellular domains of the latter. This is in contrast to our previous study, which revealed that fibrin interacts only with the third extracellular domain of VE-cadherin. In conclusion, our study identified N-cadherin as a novel receptor for fibrin and localized complementary binding sites within both fibrin and N-cadherin. The pathophysiological role of this interaction remains to be established.


  • Open Access

    LRP1 protects against excessive superior mesenteric artery remodeling by modulating angiotensin II–mediated signaling

    by Jackie M. Zhang, Dianaly T. Au, Hisashi Sawada, Michael K. Franklin, Jessica J. Moorleghen, Deborah A. Howatt, Pengjun Wang, Brittany O. Aicher, Brian Hampton, Mary Migliorini, et al.

    Vascular smooth muscle cells (vSMCs) exert a critical role in sensing and maintaining vascular integrity. These cells abundantly express the low-density lipoprotein receptor–related protein 1 (LRP1), a large endocytic signaling receptor that recognizes numerous ligands, including apolipoprotein E–rich lipoproteins, proteases, and protease-inhibitor complexes. We observed the spontaneous formation of aneurysms in the superior mesenteric artery (SMA) of both male and female mice in which LRP1 was genetically deleted in vSMCs (smLRP1 –/– mice). Quantitative proteomics revealed elevated abundance of several proteins in smLRP1 –/– mice that are known to be induced by angiotensin II–mediated (AngII-mediated) signaling, suggesting that this pathway was dysregulated. Administration of losartan, an AngII type I receptor antagonist, or an angiotensinogen antisense oligonucleotide to reduce plasma angiotensinogen concentrations restored the normal SMA phenotype in smLRP1 –/– mice and prevented aneurysm formation. Additionally, using a vascular injury model, we noted excessive vascular remodeling and neointima formation in smLRP1 –/– mice that was restored by losartan administration. Together, these findings reveal that LRP1 regulates vascular integrity and remodeling of the SMA by attenuating excessive AngII-mediated signaling.


  • Open Access

    Characterization of interaction between blood coagulation factor VIII and LRP1 suggests dynamic binding by alternating complex contacts

    by Haarin Chun, James H. Kurasawa, Philip Olivares, Ekaterina S. Marakasova, Svetlana A. Shestopal, Gabriela U. Hassink, Elena Karnaukhova, Mary Migliorini, Juliet O. Obi, Ally K. Smith, et al.